Drug Profile
SYGN 303
Alternative Names: SYGN-303Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Synedgen
- Class Polysaccharides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Intestinal obstruction
Most Recent Events
- 12 Sep 2023 SYGN 303 is still in preclinical development for Intestinal-obstruction in USA (PO) (Synedgen pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Intestinal-obstruction in USA (PO)
- 27 Oct 2016 Pharmacodynamics data from a preclinical study in Intestinal obstruction in cystic fibrosis released by Synedgen